Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study
暂无分享,去创建一个
S. Duquennoy | S. Fafi-Kremer | B. Hurault de Ligny | E. Morelon | B. Moulin | N. Bouvier | S. Caillard | A. Conrad | N. Keller
[1] R. Porcher,et al. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.
[2] T. Mohanakumar,et al. Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. , 2017, Journal of the American Society of Nephrology : JASN.
[3] J. Chapman,et al. Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin , 2017, Transplantation direct.
[4] M. Halim,et al. Long-Term Follow-Up of Active Treatment Versus Minimization of Immunosuppressive Agents in Patients With BK Virus-Associated Nephropathy After Kidney Transplant. , 2016, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
[5] N. Babel,et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] Devin Tian,et al. The impact of surveillance and rapid reduction in immunosuppression to control BK virus‐related graft injury in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[7] L. Braun-Parvez,et al. Risk Factors for BK Virus Infection in the Era of Therapeutic Drug Monitoring , 2013, Transplantation.
[8] P. Randhawa,et al. BK Polyomavirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] C. Bratton,et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[10] G. Mourad,et al. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients , 2011, Transplant infectious disease : an official journal of the Transplantation Society.
[11] D. Muruve,et al. Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Toward a New Therapy for BK Virus Infection , 2010, Transplantation.
[12] M. Mihatsch,et al. Reducing Immunosuppression Preserves Allograft Function in Presumptive and Definitive Polyomavirus‐Associated Nephropathy , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] E. Woodle,et al. Assessment of Efficacy and Safety of FK778 in Comparison With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy , 2010, Transplantation.
[14] Steve Doucette,et al. Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review , 2010, Transplantation.
[15] K. Abbott,et al. Retransplantation After BK Virus Nephropathy in Prior Kidney Transplant: An OPTN Database Analysis , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[16] H. Hirsch,et al. Leflunomide Inhibition of BK Virus Replication in Renal Tubular Epithelial Cells , 2009, Journal of Virology.
[17] T. Benzing,et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. , 2009, Transplantation proceedings.
[18] J. Schold,et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States , 2009, Transplant international : official journal of the European Society for Organ Transplantation.
[19] I. D. de Boer,et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[20] G. Mourad,et al. Does Reduction in Immunosuppression in Viremic Patients Prevent BK Virus Nephropathy in De Novo Renal Transplant Recipients? A Prospective Study , 2008, Transplantation.
[21] R. Orentas,et al. Successful Treatment of BK Viremia Using Reduction in Immunosuppression Without Antiviral Therapy , 2008, Transplantation.
[22] C. Mengelle,et al. Leflunomide treatment for polyomavirus BK‐associated nephropathy after kidney transplantation , 2007, Transplant international : official journal of the European Society for Organ Transplantation.
[23] C. Mengelle,et al. Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. , 2007, Transplantation proceedings.
[24] J. Jordan,et al. Treatment of Renal Allograft Polyoma BK Virus Infection with Leflunomide , 2006, Transplantation.
[25] S. Hariharan,et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. , 2005, Kidney international.
[26] W. Al-Nakib,et al. BK virus nephropathy in renal transplant recipients in Kuwait: a preliminary report. , 2005, Transplantation proceedings.
[27] J. Millis,et al. Leflunomide for polyomavirus type BK nephropathy. , 2005, The New England journal of medicine.
[28] M. Schnitzler,et al. Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[29] P. Randhawa,et al. Effect of Leflunomide and Cidofovir on Replication of BK Virus in an In Vitro Culture System , 2005, Transplantation.
[30] M. Schnitzler,et al. Prospective, Pilot, Open‐Label, Short‐Term Study of Conversion to Leflunomide Reverses Chronic Renal Allograft Dysfunction , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] T. Klimkait,et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. , 2002, The New England journal of medicine.
[32] J. Fink,et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. , 2002, Journal of the American Society of Nephrology : JASN.
[33] A. Chong,et al. Experiences with leflunomide in solid organ transplantation. , 2002, Transplantation.
[34] K. Khalili,et al. Human Polyomaviruses: Molecular and Clinical Perspectives , 2002 .
[35] J. Fink,et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. , 2002, Clinical transplants.
[36] D. Knight,et al. Inhibition of Cytomegalovirus in vitro and in vivo by the Experimental Immunosuppressive Agent Leflunomide , 2000, Intervirology.
[37] F. Uckun,et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* , 1999, The Journal of Biological Chemistry.
[38] A. Chong,et al. Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide (*) , 1995, The Journal of Biological Chemistry.
[39] A. Chong,et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. , 1994, Transplantation.
[40] K. Shah,et al. High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. , 1973, The Journal of infectious diseases.